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Increased Plasma Brain Natriurtic Peptide
Predicts Vascular Response in Patients with
Hypertophic Cardiomyopathy
Krishna Prasad. Andrew Grace. Alistair K.B. Slade. David Gordon. Carol A. Page. A.
John Camm. David W. Holt William J. McKenna. Department of Cardiological
Sciences, Sf George's Hospital Medical School, London, United Kingdom
Expression of m-RNA encoding Brain natriuretic peptide is increased in hy-
pertrophic cardiomyopathy (HCM). We determined both Atrial natriuretic
peptide IANP) and Brain natriuretic peptide (BNP) in 62 patients [42 males; 20
females] with hypertrophic cardiomyopathy (mean age 43 ± 15 yrs) and 25
age (mean 36 ± 12 yrs) and sex matched healthy controls. All subjects were
sampled in the unfasted ambulant state while attending the clinic at this hos-
pital. All patients had good left ventricular function assessed by 2-D echocar-
diography. Both peptides were assayed using a sensitive radioimmunoassay.
The Plama BNP in patients (mean; 81.1 pg/ml) was 6 times higher than con-
trols (mean; 13.1 pg/ml): Plasma ANP was twice (111.2 pg/ml) the control
value (50.3 pg/ml). BNP correlated with septal thickness and left ventricular
wall thickness Ir = 0.48 (p < 0.01). and r = 0.63 (p < 0.001) respectively].
BNP was significantly higher in NYHA classes II In = 22; 84.6 pg/ml) and III (n
= 13; 113.2 pg/ml) than NYHA-I; (n ~ 27: 62.5 pg/ml;)[p < 0.005]. Patients
with chest pain (n = 38), both atypical [(n = 20;) 88.14 pg/ml], and typical
[In = 18;) 100.5 pg/ml] had higher BNP levels than those without (n = 24)
[60.45 pg/ml]. BNP was higher in those with exercise hypotension (n = 31)
67.8 pg/ml vs 94.8 pg/ml [p = 0.025] and syncope/pre-syncope (n = 25) (p =
0.06); but similar in those with (n = 31) or without (n = 331 outflow obstruc-
tion ILVOTOJ Plama AN Pwas not different in any of the groups. The left atrial
size did not correlate with levels of either peptide (ANP or BNP).
In conclusion, plasma BNP is significantly elevated in HCM. Elevated levels
are associated with symptoms, markers of disease severity and exercise hy-
potension (unrelated to severity of HCM). This association of high BNP with
exercise hypotension has etiological implications and needs further study.
plasma catecholamine responses to exercise were altered in HCM.
Methods: 17 patients with HCM (15 male, 2 female, mean age: 54 ± 2) and
17 age-sex matched controls were evaluated by submaximal treadmill exer-
cise test using Bruce protocol. Plasma norepinephrine (NE) and epinephrine
(E) were measured at rest, at the end of each stage during exercise and im-
mediately after exercise.
Resu/ts: Exercise duration was shorter in HCM (Control vs HCM: 11.2 ± 0.6
vs 8.7 ± 0.6 min, p < 0.01). Mean blood pressure were higher at stage 1(100
± 10vs 109±3mmHg, p < 0.05) and at stage 11(101 ±3vs 112±3 mmHg,
p < 0.01) in HCM. Resting NE levels (151±15 vs 168±23 pg/ml, n.s.) were
not different. but NE at stage I (253 ± 25 vs 400 ± 57 pg/ml, p < 0.05) and at
stage II (314 ± 31 vs 550 ± 89 pg/ml, p < 0.05) were significantly higher in
HCM. Peak NE levels (534 ± 52 vs 724 ± 102 pg/ml, n.s.) were insignificantly
higher in HCM. Heart rate response was similar in both groups, but the ratio
of the increment in heart rate divided by the increment in NEat stage I (0.47
± 0.09 vs 0.17 ± 0.03, p<0.01) and at stage II (0.37 ± 0.05 vs 0.20 ± 0.04, P <
0.05) were significantly less in HCM. There were no difference in E responses
during exercise in both groups.
Conclusion: Patients with HCM had augmented plasma NE levels dur-
ing submaximal treadmill exercise test with higher blood pressure response
compared to controls. In addition, chronotropic sympathetic responsiveness
was impaired in patients with HCM.
Hypertrophic Cardiomyopathy in Tuscany: More
Benign Clinical Course and Outcome in an
Unselected Regional Population
Franco Cecchi. lacopo Olivotto, Alessio Montereggi, Gennaro Santoro.
Alberto Dolara, Barry J. Maron. Cardiologia S. Luca, Ospedale di Caregg( Florence,
Italy; Minneapolis Heart Institute Foundation, Minneapolis, MN
Syncope in Hypertrophic Cardiomyopathy: Use
and Interest of Atrial Programmed Stimulation
Most available information on the clinical course and prognosis of hyper-
trophic cardiomyopathy (HCM) is based on data from tertiary referral cen-
ters, potentially constituting a skewed perspective of the overall disease
spectrum. We have analyzed a community-based HCM cohort from the well-
defined geographic region of Tuscany in central Italy, which was virtually free
of such selection bias and probably more closely representative of the true
patient population with this disease. The study group comprised 202 pts,
aged 1-74 years at diagnosis (mean 41), and followed for 1-30 years (mean
10). With standard medical treatment, most pts (148; 74%) were symptomat-
ically stable or improved; the other pts (54; 26%) died of HCM-related causes
or deteriorated. Of the 13 pts who died, 11 had progressive heart failure
(6 end-stage) and only 2 died suddenly. Overall annual mortality rate was
0.6%, and just 0.1 % due to sudden cardiac death. Cumulative survival was
97%, 95%, 92% at 5. 10, 15 years follow-up. Atrial fibrillation (AF) was a
common (57. 28%) and particularly unfavorable clinical development (death
in 10/57). In conclusion, HCM in an unselected regional population: 1) has
a much more benign prognosis than previously considered, based on the
experience of referral institutions; 2) shows disease progression and heart
failure in only a minority of pts, but particularly those predisposed to AF; 3)
uncommonly causes sudden cardiac death.
Beatrice Brembilla-Perrot Alain Jacquot. Daniel Beurrier. Cardiologie A. CHU of
Brabois 54500 Vandaeuvre les Nancy France
Ventricular arrhythmias are generally reported as the most frequent cause of
syncope in hypertrophic cardiomyopathy (HeM). However non invasive and
invasive studies do not always permit to prove its mechanism. The purpose
of the study was to determine whether programmed atrial stimulation can
improve the diagnosis of unexplained syncope. Programmed atrial stimula-
tion using up to 2 extrastimuli at 3 cycle lengths (sinus, 600, 400 ms) was sys-
tematically performed in 49 patients with HCM. 32 of them had unexplained
dizziness or syncopes (group I) and 17 did not have loss of consciousness
(group II). The results were as following: Patients with the history of syncope
had the highest prevalence of sustained supraventricular tachyarrhythmia
at electrophysiological study (72%). In contrast sustained supraventricular
arrhythmia was induced in only 3 of 17 patients of group II (p < 0.05). In-
ducible supraventricular tachycardia was the only cause of the syncope in
12 patients. Antiarrhythmic therapy (Class I and betablockers) suppressed
the symptoms except in one patient who received an antiarrhythmic drug
but who developed a documented atrial fibrillation. No Holter finding nor
echocardiographic data could explain the high incidence of inducible atrial
tachycardia of these patients. Only a high mean age was noted (58 ± 12
years).
In conclusion induced atrial tachy-arrhythmias could explain most of the
syncopes of middle-aged patients with hypertrophic cardiomyopathy and
systematic programmed atrial stimulation is recommended.
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Augmented Plasma Norepinephrine and Blood
Pressure Responses to Submaximal Exercise
with Impaired Chronotropic Response In Patients
with Hypertrophic Cardiomyopathy
Coronary Sinus pH During Dipyridamole Infusion
in Patients with Angina and Hypertrophic
Cardiomyopathy
Perry M. Elliott, Giuseppe M.C. Rosano, Jaswinder Gill. Juan Carlos Kaski. Philip
A. Poole-Wilson, William J. McKenna. St. George's Hospital and National Heart and
Lung Institute, London, u.K.
Typical angina pectoris and myocardial scarring suggestive of ischemia are
common in patients with hypertrophic cardiomyopathy (HCM). However. the
clinical evaluation of myocardial ischemia in HCM remains problematic as
baseline ECG abnormalities are frequent and thallium-201 perfusion abnor-
malities correlate poorly with anginal symptoms. Similarly, coronary sinus
lactate studies are subject to sampling errors. Coronary sinus pH measure-
ment using a catheter mounted pH electrode is a validated, sensitive tech-
nique for the detection of myocardial ischemia. The change in coronary si-
nus pH during Lv. dipyridamole was determined in 10 patients with HCM
and typical exertional chest pain (7 male, mean age 35 ± 11 years, range
19-53). Eight patients had ST segment depression of 2: 1 mm in 2 or more
leads of the baseline ECG at rest and 4 had reversible perfusion defects dur-
ing stress thallium-201 scintigraphy. The pH electrode was introduced into
the coronary sinus via the subclavian vein and dipyridamole (0.5 mgikg) ad-
ministered by slow Lv. injection. All patients experienced typical chest pain
associated with a fall in coronary sinus pH (mean 0.08 ± 0.04, range: 0.02-
0.15 units). Eight patients had changes 2:0.04 units. ST depression (2:1 mm
from baseline) occurred in 3 patients. Peak heart rate Imean 95.5 ± 12 bpm,
range 80-115) correlated with the maximal pH change (r = 0.7, P = 0.02).
There was no association between maximum pH change and left ventricular
dimensions or outflow tract gradient.
Conclusion; Chest pain during dipyridamole infusion in patients with HCM
is caused by myocardial ischemia. Coronary sinus pH electrodes can be used
successfully in the evaluation of myocardial ischemia risk in patients with
HCM.
Hiroki Omodani, Toru Kinugawa. Masahiko Kato, Noriyasu Noguchi, Shuichi Osaki,
Tatsuhiko Matsumoto, Hiroyuki Miyakoda, Hiroshi Kotake, Hiroto Mashiba. 1st
Dept. af Int. Med. Tatto,; Univ., Yonago, Japan
Background: It is reported that there maya link between abnormal cate-
cholamine metabolism and hyperthropic cardiomyopathy (HCM). However,
there are controversies about plasma catecholamine levels in patients with
HCM. Studies were limited about serial measurements in plasma cate-
cholamine during exercise. This study determined if cardiovascular and
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